Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer-Reference-Cited by-同舟云学术

Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer

Published:2014-12 Issue:6 Volume:66 Page:1125-1132
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Gandaglia Giorgio,Sun Maxine,Hu Jim C.,Novara Giacomo,Choueiri Toni K.,Nguyen Paul L.,Schiffmann Jonas,Graefen Markus,Shariat Shahrokh F.,Abdollah Firas,Briganti Alberto,Montorsi Francesco,Trinh Quoc-Dien,Karakiewicz Pierre I.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Studies on prostatic cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;Cancer Res,1941

2. Androgen deprivation therapy for prostate cancer;Sharifi;JAMA,2005

3. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma;Shahinian;Cancer,2005

4. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy;Conteduca;Crit Rev Oncol Hematol,2013

5. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?;Keating;Eur Urol,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023;Scientific Reports;2024-07-12

2. Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy;Anticancer Research;2022-12-30

3. Sex Differences in Acute Kidney Injury;Seminars in Nephrology;2022-03

4. Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy;Prostate Cancer and Prostatic Diseases;2021-11-22

5. Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer;Urologic Oncology: Seminars and Original Investigations;2021-10